An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma

Journal of the American Academy of Dermatology

Volumn 71, Issue 5, 2014, Pages 904-911.e1

  Ally, Mina Sarah ^a   Aasi, Sumaira ^a   Wysong, Ashley ^a,c   Teng, Claudia ^a   Anderson, Eric ^b   Bailey Healy, Irene ^a   Oro, Anthony ^a   Kim, Jinah ^a   Chang, Anne Lynn ^a,b   Tang, Jean Yuh ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCRIPPS CLINIC   (United States)

Author keywords

Basal cell carcinoma; Mohs; Neoadjuvant; Surgery; Surgical defect; Vismodegib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; PARAFFIN; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; AMENORRHEA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; CRYOTHERAPY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FEMALE; FOLLOW UP; HAIR LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERVENTION STUDY; MALE; MIDDLE AGED; MUSCLE CRAMP; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; VERY ELDERLY; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; CARCINOMA, BASAL CELL; CHEMICALLY INDUCED; CHEMOSURGERY; CLINICAL TRIAL; PATHOLOGY; SKIN NEOPLASMS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALOPECIA; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CHEMOTHERAPY, ADJUVANT; DYSGEUSIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MOHS SURGERY; MUSCLE CRAMP; NEOADJUVANT THERAPY; PYRIDINES; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 84922479971     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.05.020     Document Type: Article

References (20)

1. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8:743-54.
2. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171-9.
3. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366:2180-8.
4. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994;30:774-8.
5. Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol 2013;149:615-6.
6. Gulleth Y, Goldberg N, Silverman RP, Gastman BR. What is the best surgical margin for a basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg 2010;126:1222-31.
7. Aldabagh B, Yu J, Perkocha LA, Arron S. Histologic changes in basal cell carcinoma after treatment with vismodegib. Dermatol Surg 2013;39:1703-5.
8. Chang AL, Atwood SX, Tartar DM, Oro AE. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. JAMA Dermatol 2013;149:639-41.
9. Kahana A, Worden FP, Elner VM. Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma. JAMA Ophthalmol 2013;131:1364-6.
10. National Comprehensive Cancer Network (NCCN) version 2. 2013 guidelines on basal and squamous cell skin cancers. NCCN Guidelines 2013. Available at http://www.nccn.org. Accessed January 10, 2014.
11. Akcam TM, Gubisch W, Unlu H. Nonmelanoma skin cancer of the head and neck: surgical treatment. Facial Plast Surg Clin North Am 2012;20:455-71.
12. Jih MH, Friedman PM, Goldberg LH, Kimyai-Asadi A. Curettage prior to Mohs' micrographic surgery for previously biopsied nonmelanoma skin cancers: what are we curetting? Retrospective, prospective, and comparative study. Dermatol Surg 2005;31:10-5.
13. Orengo IF, Salasche SJ, Fewkes J, Khan J, Thornby J, Rubin F. Correlation of histologic subtypes of primary basal cell carcinoma and number of Mohs stages required to achieve a tumor-free plane. J Am Acad Dermatol 1997;37:395-7.
14. Siegle RJ, MacMillan J, Pollack SV. Infiltrative basal cell carcinoma: a nonsclerosing subtype. J Dermatol Surg Oncol 1986;12:830-6.
15. Paoli J, Daryoni S, Wennberg AM, Molne L, Gillstedt M, Miocic M, et al. 5-Year recurrence rates of Mohs micrographic surgery for aggressive and recurrent facial basal cell carcinoma. Acta Derm Venereol 2011;91:689-93.
16. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989;15:315-28.
17. Smeets NW, Kuijpers DI, Nelemans P, Ostertag JU, Verhaegh ME, Krekels GA, et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the faceeresults of a retrospective study and review of the literature. Br J Dermatol 2004;151:141-7.
18. Wolfe CM, Green WH, Cognetta AB Jr, Hatfield HK. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg 2012;38:1863-6.
19. Van Der Geer S, Martens J, Van Roij J, Brand E, Ostertag JU, Verhaegh ME, et al. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study. Br J Dermatol 2012;167:110-5.
20. Han A, Chen EH, Niedt G, Sherman W, Ratner D. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009;145:792-6.